Oncotarget

Research Perspectives:

Real-world evidence to guide healthcare policies in oncology

PDF  |  Full Text  |  How to cite

Oncotarget. 2019; 10:4513-4515. https://doi.org/10.18632/oncotarget.27077

Metrics: PDF 1558 views  |  Full Text 2427 views

Marco Donia1, Steen Werner Hansen2 and Inge Marie Svane1

1 National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Herlev, Denmark

2 Head Office, Herlev and Gentofte Hospital, Herlev, Denmark

Correspondence to:

Marco Donia,email: [email protected]
Inge Marie Svane,email: [email protected]

Keywords: real-world evidence; real-world data; clinical trial eligibility

Received: June 02, 2019     Accepted: June 19, 2018     Published: July 16, 2019

ABSTRACT

Randomized controlled clinical trials (RCTs) in oncology enroll patients who meet strict protocol-specified criteria. Many of these criteria overlap across multiple RCTs. A vast proportion of patients with metastatic cancer do not meet such criteria. Hence, patient populations encountered in clinical practice are essentially different from RCT-populations, questioning the representativeness of these trials. A real-world evidence approach, using data from clinical practice, is increasingly employed to complement the information on drug safety and efficacy obtained from traditional clinical trials.